Form 4: Avanos Medical SVP Mojirade James Reports Stock Transactions
SEC Form 4 Filing
A Form 4 filing reveals that Mojirade James, SVP and General Counsel of Avanos Medical, Inc., executed transactions involving common stock and performance-based restricted share units (PRSUs) on March 4, 2025.
Summary
- On March 4, 2025, Mojirade James, SVP and General Counsel of Avanos Medical, Inc., engaged in transactions involving the company's common stock.
- These transactions included the vesting of 8,039 performance-based restricted share units (PRSUs) awarded on March 4, 2022.
- Shares were also surrendered to the issuer to satisfy tax withholding obligations upon the vesting of both PRSUs and time-based restricted share units (TRSUs).
- Specifically, 2,636 shares were surrendered at a price of $15.13 to cover taxes related to the PRSU vesting.
- An additional 2,068 shares were surrendered at $15.13 to cover taxes related to the vesting of 6,880 TRSUs awarded on March 4, 2022.
- Following these transactions, James directly owns 73,648 shares of Avanos Medical, Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Positives
- The vesting of restricted share units indicates that performance or time-based milestones were achieved.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives, ensuring compliance with SEC regulations.
- The vesting of restricted stock units is a common form of executive compensation, aligning management's interests with those of shareholders.
Stakeholder Impact
- The transactions reported in the Form 4 filing may be of interest to shareholders, as they provide insight into the actions of company executives.
Key Dates
| Date | Description |
|---|---|
| 03/04/2022 | Date PRSUs and TRSUs were awarded to the Reporting Person |
| 03/04/2025 | Date of earliest transaction, vesting of PRSUs and TRSUs, and surrender of shares for tax obligations |
| 03/06/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.